Cipla Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 7,67,139 shares,. Its Average Traded Price (ATP) is ₹1371.09, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹1384.10.
Cipla has an upper circuit limit of ₹1524.70 and a lower circuit limit of ₹1247.50. The total value traded stands at ₹105.18 CR, and the delivery percentage for the day is 47.2%.
The stock is currently traded with a market lot size of 1. Cipla also offers a dividend yield of 0.94%.
Cipla Share Price Chart
Cipla Share Key Metrics
Volume
7.67 L
Market Cap
111813.87 CR
LTQ@LTP
1@1384.10
ATP
1371.09
Var Margin
12.5 %
Circuit Range
1247.5-1524.7
Delivery %
47.2 %
Value
105.18 CR
ASM/GSM
No
Market Lot
1
Cipla Resistance and Support
Pivot 1389.87
Resistance
First Resistance
1401.44
Second Resistance
1416.77
Third Resistance
1428.34
Support
First Support
1374.54
Second Support
1362.97
Third Support
1347.64
Cipla Futures & Options
1384.1
-2 (-0.14%)
Cipla Option Chain
View Price, OI, Greeks & More...
29SEP26
1381.70
-2.60 (0.19%)
27OCT26
1390.90
-0.30 (0.02%)
23NOV26
1395.80
-1.40 (0.10%)
CIPLA|29SEP26 CE 1380.00
14.50
-1.5 (-9.38%)
CIPLA|29SEP26 PE 1390.00
17.15
0.15 (0.88%)
Cipla Shareholding Pattern
View More- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Cipla Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-23 | Quarterly Results |
| 2026-05-13 | Audited Results & Final Dividend |
| 2026-01-23 | Quarterly Results |
| 2025-10-30 | Quarterly Results |
| 2025-07-25 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-01-28 | Quarterly Results |
| 2024-10-29 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-06-05 | 2026-06-05 | View More |
Cipla News
Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla has received an Environmental, Social, and Governance (ESG) rating of 68 from Niche, a SEBI registered ESG Rating Provider. The company was informed of this rating via exchange alerts on September 17, 2026.
Sep 18 2026 17:32:55
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cipla announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar to Keytruda (Pembrolizumab), in the US. Cipla USA will be responsible for commercialization, leveraging its strong presence in the market.
Sep 03 2026 20:06:21
Cipla Ltd - 500087 - Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company
Cipla announced NCLT approval to proceed with the scheme of amalgamation with Inzpera Healthsciences. Shareholders and creditors have 30 days to submit representations to NCLT for the proposed merger.
Sep 03 2026 16:43:06
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cipla and SBP Group announced an exclusive licensing agreement for Rolditamig Deuderuxtecan (TQB2102), a HER2 bispecific ADC. The agreement grants Cipla rights to develop and commercialize the drug in India, South Africa, and five other emerging markets, aiming to accelerate patient access.
Aug 31 2026 15:42:53
Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, received a Voluntary Action Indicated (VAI) classification from the USFDA for its Unit 3 manufacturing facility in Central Islip, Long Island, NY. This classification indicates that while objectionable conditions were found during the July 2026 inspection, no regulatory action is currently warranted.
Aug 28 2026 21:17:08
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Restructuring
Cipla undertook a group restructuring to rationalize and simplify its structure. Aspergen Limited, India, a joint venture, acquired 100% stake in Aspergen Inc., USA, from Cipla (EU) Limited and Kemwell Biopharma UK Limited.
Aug 27 2026 20:15:05
Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Cipla will host two in-person analyst and institutional investor meetings in September 2026. The meetings include the Jefferies India Forum Conference in Gurgaon on September 17 and the Kotak Healthcare Conference in Mumbai on September 18.
Aug 27 2026 14:48:27
Cipla Ltd - 500087 - USFDA Inspection At Company'S Manufacturing Facility In Pithampur, India
Cipla's Pithampur manufacturing facility underwent a USFDA cGMP inspection from August 17-25, 2026, and received seven inspectional observations in Form 483. The company is committed to addressing these observations.
Aug 25 2026 16:02:50
Cipla Management
| Name | Position |
|---|---|
| Y K Hamied | Chairman |
| Kamil Hamied | Non Independent & Non Executive Director |
Cipla Similar Stocks
Divi's Laboratories Ltd.
9352.00
-58.50 (0.62%)
Torrent Pharmaceuticals Ltd.
4935.00
-35.00 (0.70%)
Apollo Hospitals Enterprise Ltd.
8835.50
-76.50 (0.86%)
Lenskart Solutions Ltd.
691.45
7.60 (1.11%)
Zydus Lifesciences Ltd.
1162.30
1.30 (0.11%)
Laurus Labs Ltd.
2006.50
-11.00 (0.55%)
Max Healthcare Institute Ltd.
1056.50
-10.10 (0.95%)
Aurobindo Pharma Ltd.
1700.00
-13.40 (0.78%)
Lupin Ltd.
2135.00
10.50 (0.49%)
Dr. Reddy's Laboratories Ltd.
1211.00
12.70 (1.06%)
Cipla FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in CIPLA
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
+ Free 1st Year AMC